- Madrigal Pharmaceuticals recently reported quarterly results for the period ended September 2026 and is preparing to share new data on Rezdiffra at AASLD's The Liver Meeting 2026, including clinical and real world evidence across more than 12,000 patients.
- The scale of the RESONANCE program and the focus on effectiveness, tolerability, treatment persistence, and cardiovascular markers gives investors a clearer view of how Rezdiffra is being used in everyday MASH care.
- We will now look at how Madrigal Pharmaceuticals' investment narrative could be influenced by the upcoming Rezdiffra real world data presentations.
Madrigal Pharmaceuticals Investment Narrative Recap
To own Madrigal Pharmaceuticals, you need to believe Rezdiffra can support a durable MASH franchise while the rest of the portfolio and international efforts scale up. The near term focus sits on execution. That means converting clinical and real world momentum into consistent prescription trends, while keeping spending in check so losses do not balloon as the footprint grows.
The biggest short term swing factor is how upcoming earnings on 3 November frame Rezdiffra demand, payer access, and operating discipline. The key risk is still concentration. Any wobble in efficacy signals, safety, reimbursement, or competitive positioning around this single therapy could quickly reshape the business outlook.
The most relevant update here is Madrigal Pharmaceuticals preparing to share 13 new Rezdiffra abstracts from the RESONANCE program at AASLD’s The Liver Meeting 2026. Real world data across more than 12,000 patients gives investors a closer look at effectiveness, tolerability, persistence, and cardiometabolic markers outside tightly controlled trials.
For you, that evidence directly ties into the main catalysts and risks. Strong, consistent outcomes would support the case for broader use, help payer discussions, and frame upcoming quarters ahead of and beyond the November earnings release. Any mixed signals would not be conclusive alone, but would raise the bar on execution and future data readouts.
What The Current Madrigal Pharmaceuticals Forecasts Assume
Madrigal Pharmaceuticals' narrative projects US$3.2b in revenue and US$935.6m in earnings by 2029. Analysts are building that view on revenue growing around 42% a year and on earnings moving from a loss of US$309.4m today to US$935.6m. This represents roughly a US$1.25b swing into profit over that period.
Uncover how Madrigal Pharmaceuticals' fair value indicates a 54% potential upside to its current price, which could narrow quickly if expectations keep tightening.
Exploring Other Perspectives
You might see Madrigal Pharmaceuticals very differently if you focus on the bullish catalyst that Rezdiffra becomes a first choice MASH therapy. The most optimistic analysts were penciling in revenue of about US$4.1b and earnings near US$1.4b by 2029, far above the lower earnings expectations, and those views have not yet reflected the incoming real world data.
Explore 5 other Madrigal Pharmaceuticals fair value estimates, including one that suggests potential upside of as much as 237% from the current price.
Decide For Yourself
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Madrigal Pharmaceuticals research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
- See our latest analysis for Madrigal Pharmaceuticals. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Madrigal Pharmaceuticals' overall financial health at a glance.
Looking For More Investment Ideas Beyond Madrigal Pharmaceuticals?
If you want to cross check your view on Madrigal Pharmaceuticals against other opportunities, the Simply Wall St Screener lets you filter for traits that matter to you and compare businesses side by side.
- If you care most about valuation and business quality, scan through 29 high quality undervalued stocks that combine stronger fundamentals with prices that may not fully reflect them.
- For investors who prefer resilience over excitement, review a curated 30 resilient stocks with low risk scores that scores well on financial strength and risk metrics.
- If you want to get ahead of the crowd, comb through a focused 21 high quality undiscovered gems that highlight underfollowed companies with solid underlying numbers.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com